EpiPen pricing scandal has sent Mylan stock below $40 and to 52-week lows. Teva failed in its attempt to acquire Mylan last year. Mylan's reduced market capitalization could whet its appetite once ...

Source: Teva Pharmaceutical via Facebook. What: Shares of Mylan, a branded-drug developer that is alsoa large player in the generic drug market, surged by 22% in April, according to data from S&P ...

Going by the historical performance, we believe that the stock price of Mylan (NYSE: MYL), a pharmaceutical company best known for its generic drugs, could offer an upside of over 45% from the current ...

Mylan, a company best known for generic drugs, watched its stock slide last year after it was named along with other generic-drug manufacturers in a case alleging price-fixing. The lawsuit, brought by ...

Shares of Mylan (NYSE:MYL) plunged in Wednesday trading after the company reported disappointing fourth-quarter results. Mylan stock fell as much as 15% as a result and made new 52-week lows. This ...

The Novo Nordisk A/S (NYSE:NVO) attempt to block Mylan Pharmaceuticals from launching a generic version of its weight-loss drug Wegovy hit a major obstacle as the court ruled in Mylan's favor on key ...

A bull signal flashing for MYL could give its recent rally a big boost U.K.-based pharmaceutical name Mylan NV (NASDAQ:MYL) has been in rebound mode these past couple months, bouncing off a familiar ...

The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our readers all have their own perspectives, so we are always ...

Mylan NV (NASDAQ:MYL) is down 0.7%, last seen trading at $15.39, amid news that the pharmaceutical company named Chairman Robert Coury to be the new executive chairman, the second time Coury has been ...

Shares of Mylan were up 6% in trading on Thursday after the drugmaker restarted production of hydroxychloroquine-sulfate tablets, which are being considered as a possible treatment for people with ...